WHO ICTRP trial
A Study of Macitentan in Healthy Chinese Adult Male Participants
NCT05959941 · NIH Clinical Trials · Recruiting
Key facts
| Trial ID | NCT05959941 |
|---|---|
| Public title | A Study of Macitentan in Healthy Chinese Adult Male Participants |
| Scientific title | A Double-blind, Randomized, Placebo-controlled, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Macitentan 75 mg in Healthy Chinese Adult Male Participants |
| Primary sponsor | Actelion |
| Registry | NIH Clinical Trials |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | China |
| Conditions | Healthy |
| Interventions | Drug: Macitentan;Drug: Placebo |
| Registration date | Jul 18, 2023 |
| Target size | 12 |
| Secondary IDs | 67896062PAH1009;CR109324 |
| Registry page | clinicaltrials.gov |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: